Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-interval lanreotide Autogel in biochemically controlled acromegaly previously treated with octreotide LAR
NL-OMON38013Phase 4Active, not recruiting
- Sponsor
- Ipsen
- Start
- Dec 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of lanreotide in acromegaly and gigantism (3 arms), sponsored by Ipsen. Primary endpoint: Maintenance or extension of injection interval with normalized IGF-1 at Week 48. Started Dec 2008; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
acromegalygigantism
Beyond the preview
Go deeper on NL-OMON38013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38013.